Gerald E. Quirk - 11 Oct 2022 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Chief Legal Officer
Signature
/s/ Todd Rosenthal, as attorney-in-fact
Issuer symbol
SYRS
Transactions as of
11 Oct 2022
Transactions value $
$0
Form type
4
Filing time
13 Oct 2022, 16:20:07 UTC
Next filing
14 Sep 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Restricted Stock Units Award $0 +45K $0.00 45K 11 Oct 2022 Common Stock 45K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
F2 These RSUs will vest as to one half (50%) of the shares on October 11, 2023, and as to one half (50%) of the shares on March 31, 2024.